

Stem Cell New Drug Development

PO-CHENG LIN

Gwo Xi Stem Cell Applied Technology Co., Ltd. RD CTO

The discovery and clinical application of stem cells has gone through nearly sixty years. In the early days, due to limitations in technical capabilities, stem cell technology almost consisted of simple stem cell collection and transplantation (i.e. minimal manipulation and homologous use). Therefore, stem cell therapy was regarded as a medical technology at that time. However, with the advances in science, the research and application of stem cells have undergone significant changes. The main difference is that the manufacturing process of stem cells has moved beyond the laboratory and into commercial production. Stem cells are now increasingly seen as a medical product for disease treatment. Gwo Xi Stem Cell Company has been active in the field of stem cell new drug research and development since 2010. In the stem cell manufacturing process, we employ innovative small molecule induction technology (i.e. Nigiro-Med®) and advanced stem cell modular manufacturing processes to successfully create a number of stem cell preparations that comply with pharmaceutical regulations. These stem cell preparations have been gradually developed into human clinical trials and have shown promising progress. At the same time, Taiwan has also made major breakthroughs in the regulatory management system for regenerative medicine. The first dual-track regenerative medicine management structure. Such a system allows regenerative medicine to develop both in terms of technology application and drug development. Innovative management approaches enable regenerative medicine to provide reasonable urgent medical needs under strict quality control.

